Rebecca Taub

2020

In 2020, Rebecca Taub earned a total compensation of $3.9M as President, Research &Development and Chief Medical Officer at Synta Pharmaceuticals, a 26% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$339,230
Option Awards$3,052,280
Salary$490,833
Total$3,882,343

Taub received $3.1M in option awards, accounting for 79% of the total pay in 2020.

Taub also received $339.2K in non-equity incentive plan and $490.8K in salary.

Rankings

In 2020, Rebecca Taub's compensation ranked 2,949th out of 13,090 executives tracked by ExecPay. In other words, Taub earned more than 77.5% of executives.

ClassificationRankingPercentile
All
2,949
out of 13,090
78th
Division
Manufacturing
1,144
out of 5,618
80th
Major group
Chemicals And Allied Products
425
out of 2,251
81st
Industry group
Drugs
368
out of 1,951
81st
Industry
Pharmaceutical Preparations
271
out of 1,456
81st
Source: SEC filing on May 2, 2022.

Taub's colleagues

We found four more compensation records of executives who worked with Rebecca Taub at Synta Pharmaceuticals in 2020.

2020

Paul Friedman

Synta Pharmaceuticals

Chief Executive Officer

2020

Brian Lynch

Synta Pharmaceuticals

General Counsel

2020

Remy Sukhija

Synta Pharmaceuticals

Senior Vice President, Chief Commercial Officer

2020

Marc Schneebaum

Synta Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like